Cure rate of childhood B cell lymphoma with rituximab and reduced strength of chemotherapy

Phase 2

• Conditions: Health Condition 1: null- Burkitt lymphoma and diffuse large B cell lymphoma

• Registration Number: CTRI/2017/09/009650
• Lead Sponsor: Cancer Institute adyar

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.CD 20 positive Burkitt lymphoma & Diffuse large B cell lymphoma stage III & IV stage

2.CD 20 positive Burkitt lymphoma & Diffuse large B cell lymphoma stage I & II stage non-resectable

Exclusion Criteria

1.Active hepatitis B infection or carriers of hepatitis B virus

2.Active hepatitis C infection or carriers of hepatitis C virus

3.HIV infected children

4.Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ transplantation, previous malignancy of any type, or known positive HIV serology

5.Follicular lymphoma, MALT, nodular marginal zone lymphoma and primary mediastinal B cell lymphoma

6.Children with cardiac dysfunction- ejection fraction < 45%

7.Pregnancy

8.Allergic to rituximab

9.Not consenting for treatment

10.Children assessed by treating physician as not fit for intensive chemotherapy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To evaluate the efficacy of treatment schedule utilizing addition of rituximab to reduced dosage standard LMB backbone chemotherapy.Timepoint: To evaluate the efficacy of treatment schedule utilizing addition of rituximab to reduced dosage standard LMB backbone chemotherapy.

Secondary Outcome Measures

Name	Time	Method
To evaluate the toxicity profile of treatment schedule utilizing addition of rituximab to reduced dosage standard LMB backbone chemotherapy.Timepoint: During chemotherapy treatment